Fact checked byMindy Valcarcel, MS

Read more

March 21, 2023
1 min read
Save

Axicabtagene ciloleucel significantly extends survival in large B-cell lymphoma

Fact checked byMindy Valcarcel, MS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.

Results of the randomized phase 3 ZUMA-7 study showed the improvement in OS, a prespecified key secondary endpoint, among patients who were refractory to first-line chemoimmunotherapy or experienced disease relapse within 12 months of initial treatment.

CAR T-cell therapy, 3d rendering
As initial treatment for adults with relapsed/refractory large B-cell lymphoma, axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences) demonstrated a statistically significant improvement in survival vs. historic treatment, according to a Kite Pharma press release. Image: Adobe Stock

Axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences) — also known as axi-cel — is an autologous, gene-edited, CD19-directed chimeric antigen receptor T-cell therapy. FDA approved axi-cel last year as initial treatment of relapsed/refractory large B-cell lymphoma based on data from the ZUMA-7 trial.

ZUMA-7 examined the safety and efficacy of axi-cel vs. standard of care among 359 adults with relapsed or refractory large B-cell lymphoma at 77 centers worldwide. Standard of care consists of a platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy and autologous hematopoietic stem cell transplantation for responders to the chemoimmunotherapy.

EFS served as the primary endpoint.

Results showed a 2.5-fold increase compared with standard of care in the percentage of patients alive at 2 years who did not experience disease progression or require additional cancer treatment (40.5% vs. 16.3%). Researchers reported a fourfold increase in median EFS (8.3 months vs. 2 months; HR = 0.39; 95% CI, 0.3-0.51) with axi-cel vs. standard of care, as well as higher rates of overall response (83% vs. 50%; OR = 5.31; 95% CI, 3.1-8.9) and complete response (65% vs. 32%).

An interim OS analysis occurred at the time of the primary EFS analysis, with the prespecified primary OS analysis to be conducted after 210 deaths or no later than 5 years after random assignment of the first patient in the trial, according to a Kite press release.

Axi-cel had a safety profile consistent with that of prior studies. Grade 3 or higher cytokine release syndrome occurred among 7% and neurologic events among 25% of the 168 safety-evaluable patients who received axi-cel. Most patients in the standard-of-care group (83%) experienced high-grade events, mostly cytopenias.

Complete results will be presented at a medical meeting later this year, according to the press release.